DDX53 and neoplasm: Knowing that CT26 is an immunologically “hot” tumor model49, we found it important to assess whether treating tumors with 4-OI and/or VSVΔ51 would influence the presence of immune subsets in the tumor microenvironment (TME) as well as the lymphoid organs.